Literature DB >> 26518294

Economic Evidence of Pneumococcal Vaccination in Older Adults: Uncertain Modelling or Competitive Tendering?

Livio Garattini1, Anna Padula2, Milene Rangel Da Costa2,3.   

Abstract

Mesh：

Substances：

Year:  2016        PMID： 26518294     DOI： 10.1007/s40273-015-0341-4

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN： 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  22 in total

Review 1.  Serotype replacement in disease after pneumococcal vaccination.

Authors:  Daniel M Weinberger; Richard Malley; Marc Lipsitch
Journal:  Lancet       Date:  2011-04-12       Impact factor: 79.321

2.  Cost-effectiveness of vaccinating the elderly and at-risk adults with the 23-valent pneumococcal polysaccharide vaccine or 13-valent pneumococcal conjugate vaccine in the UK.

Authors:  Yiling Jiang; Aline Gauthier; Sam Keeping; Stuart Carroll
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2014-09-05       Impact factor: 2.217

3.  Cost-effectiveness of new adult pneumococcal vaccination strategies in Italy.

Authors:  Sara Boccalini; Angela Bechini; Miriam Levi; Emila Tiscione; Roberto Gasparini; Paolo Bonanni
Journal:  Hum Vaccin Immunother       Date:  2013-01-07       Impact factor: 3.452

4.  Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine.

Authors:  Tamara Pilishvili; Catherine Lexau; Monica M Farley; James Hadler; Lee H Harrison; Nancy M Bennett; Arthur Reingold; Ann Thomas; William Schaffner; Allen S Craig; Philip J Smith; Bernard W Beall; Cynthia G Whitney; Matthew R Moore
Journal:  J Infect Dis       Date:  2010-01-01       Impact factor: 5.226

5.  Effectiveness of pneumococcal polysaccharide vaccine in older adults.

Authors:  Lisa A Jackson; Kathleen M Neuzil; Onchee Yu; Patti Benson; William E Barlow; Annette L Adams; Christi A Hanson; Lisa D Mahoney; David K Shay; William W Thompson
Journal:  N Engl J Med       Date:  2003-05-01       Impact factor: 91.245

6.  Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-acquired pneumonia in the general population aged ≥ 60 years: 3 years of follow-up in the CAPAMIS study.

Authors:  Olga Ochoa-Gondar; Angel Vila-Corcoles; Teresa Rodriguez-Blanco; Frederic Gomez-Bertomeu; Enric Figuerola-Massana; Xavier Raga-Luria; Imma Hospital-Guardiola
Journal:  Clin Infect Dis       Date:  2014-02-13       Impact factor: 9.079

Review 7.  A review of economic evaluations of 13-valent pneumococcal conjugate vaccine (PCV13) in adults and the elderly.

Authors:  S Dirmesropian; J G Wood; C R MacIntyre; A T Newall
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

8.  Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands.

Authors:  Marie-Josée J Mangen; Mark H Rozenbaum; Susanne M Huijts; Cornelis H van Werkhoven; Douwe F Postma; Mark Atwood; Anna M M van Deursen; Arie van der Ende; Diederick E Grobbee; Elisabeth A M Sanders; Reiko Sato; Theo J M Verheij; Conrad E Vissink; Marc J M Bonten; G Ardine de Wit
Journal:  Eur Respir J       Date:  2015-07-09       Impact factor: 16.671

9.  Budget impact analysis of a pneumococcal vaccination programme in the 65-year-old Spanish cohort using a dynamic model.

Authors:  Roberto Pradas; Angel Gil de Miguel; Alejandro Álvaro; Ruth Gil-Prieto; Reyes Lorente; Cristina Méndez; Pablo Guijarro; Fernando Antoñanzas
Journal:  BMC Infect Dis       Date:  2013-04-11       Impact factor: 3.090

10.  Adult immunization with 13-valent pneumococcal vaccine in Campania region, South Italy: an economic evaluation.

Authors:  Giorgio Liguori; Antonino Parlato; Alessandro Sanduzzi Zamparelli; Patrizia Belfiore; Francesca Gallé; Valeria Di Onofrio; Carla Riganti; Bruno Zamparelli
Journal:  Hum Vaccin Immunother       Date:  2013-11-01       Impact factor: 3.452
View more
  1 in total

Review 1.  Pneumonia and Invasive Pneumococcal Diseases: The Role of Pneumococcal Conjugate Vaccine in the Era of Multi-Drug Resistance.

Authors:  Chiara Scelfo; Francesco Menzella; Matteo Fontana; Giulia Ghidoni; Carla Galeone; Nicola Cosimo Facciolongo
Journal:  Vaccines (Basel)       Date:  2021-04-22
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.